首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1771079

促紅血球生成素促效劑市場－全球產業規模、佔有率、趨勢、機會和預測（按類型、應用、地區和競爭細分，2020-2030 年）

Erythropoietin Stimulating Agents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Region & Competition, 2020-2030F

出版日期: 2025年07月14日 | 出版商:

TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年全球促紅血球生成素促效劑市值為 74.5 億美元，預計到 2030 年將以 8.14% 的複合年成長率成長。促紅血球生成素促效劑 (ESA) 是促紅血球生成素的合成形式，促紅血球生成素是一種由腎臟自然產生的糖蛋白激素，可調節骨髓中的紅血球生成。這些藥物廣泛用於治療與慢性腎臟病 (CKD)、癌症治療、HIV/AIDS 以及紅血球計數低的外科手術相關的貧血。全球貧血盛行率不斷上升，尤其是在孕婦、兒童和慢性病患者等弱勢群體中，這推動了對 ESA 療法的需求。根據 WHO 2025，貧血仍然是一個重大的全球健康問題，對低收入和農村人口的影響尤其嚴重。此外，全球人口老化更容易引發貧血，預計這將推動紅血球生成素 (ESA) 的使用量持續成長。 ESA 在改善患者生活品質方面發揮著至關重要的作用，使其成為治療與貧血相關的慢性和急性疾病的重要組成部分。

市場概覽
預測期	2026-2030
2024年市場規模	74.5億美元
2030年市場規模	118.2億美元
2025-2030 年複合年成長率	8.14%
成長最快的領域	依泊汀阿爾法
最大的市場	北美洲

關鍵市場促進因素

腫瘤學進展

主要市場挑戰

專利到期

主要市場趨勢

轉向 Epoetin 生物類似藥

The Global Erythropoietin Stimulating Agents Market was valued at USD 7.45 billion in 2024 and is projected to grow at a CAGR of 8.14% through 2030. Erythropoietin Stimulating Agents (ESAs) are synthetic forms of erythropoietin, a glycoprotein hormone naturally produced by the kidneys that regulates red blood cell production in the bone marrow. These agents are widely used to treat anemia associated with chronic kidney disease (CKD), cancer therapies, HIV/AIDS, and surgical procedures where red blood cell counts are low. The increasing global prevalence of anemia, especially in vulnerable populations such as pregnant women, children, and individuals with chronic illnesses, is driving demand for ESA therapies. According to WHO 2025, anemia remains a significant global health issue, disproportionately affecting low-income and rural populations. Furthermore, the aging global population, which is more susceptible to conditions leading to anemia, is expected to contribute to sustained growth in ESA usage. ESAs play a crucial role in improving patient quality of life, making them a vital component in managing chronic and acute medical conditions associated with anemia.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 7.45 Billion
Market Size 2030	USD 11.82 Billion
CAGR 2025-2030	8.14%
Fastest Growing Segment	Epoetin Alfa
Largest Market	North America

Key Market Drivers

Advancements in Oncology

The rising incidence of chemotherapy-induced anemia (CIA) has led to a growing reliance on ESAs such as Epoetin Alfa and Darbepoetin Alfa to mitigate fatigue and enhance patient well-being during cancer treatment. Recent advancements in oncology have introduced more effective and targeted therapies, which may reduce the severity of anemia but also require precise supportive treatments like ESAs. Oncology research has also improved the understanding of ESA safety profiles, enabling better identification of patient subgroups that can safely benefit from these therapies. Personalized medicine and oncogenomics have further contributed to tailored ESA administration based on genetic markers and cancer types, optimizing outcomes while minimizing adverse effects. These developments have bolstered ESA integration into oncology protocols, enhancing their clinical utility and market demand.

Key Market Challenges

Patent Expirations

Patent expirations pose a significant challenge to the growth and profitability of the ESA market. As patents for key ESA drugs expire, it paves the way for the introduction of generic and biosimilar versions, intensifying market competition and driving down prices. These lower-cost alternatives often capture a substantial market share, particularly in price-sensitive healthcare systems. While this may improve patient access, it also leads to revenue declines for original ESA manufacturers. The market may become fragmented, with multiple players offering comparable products, increasing pricing pressures and reducing the incentive for continued innovation. Manufacturers are compelled to revise their pricing and market strategies to remain competitive. Although cost savings benefit healthcare systems, the shift can create challenges in ensuring consistent quality, safety, and patient trust in biosimilar products.

Key Market Trends

Shift Toward Epoetin Biosimilars

The emergence and growing acceptance of Epoetin biosimilars are significantly transforming the ESA market landscape. Biosimilars, developed to be highly similar to already approved biologics, offer equivalent safety and efficacy at a lower cost. This price advantage makes biosimilars appealing to healthcare systems and providers aiming to reduce expenditure without compromising treatment quality. The availability of Epoetin biosimilars has increased competition, expanded patient access, and driven broader adoption of ESA therapies, especially in budget-constrained regions. Regulatory approvals from agencies like the FDA and EMA have reinforced confidence in biosimilars, encouraging uptake among physicians and patients. As real-world evidence continues to support their reliability, the shift toward biosimilars is expected to further strengthen, offering substantial cost savings while maintaining treatment standards in managing anemia.

Report Scope:

In this report, the Global Erythropoietin Stimulating Agents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Erythropoietin Stimulating Agents Market, By Type:

Epoetin Alfa
Epoetin Beta
Darbepoetin Alfa
Other Types

Erythropoietin Stimulating Agents Market, By Application:

Cancer
Renal Disorders
Anti-retroviral Treatment
Neural Diseases
Other Applications

Erythropoietin Stimulating Agents Market, By Region:

North America
- United States
- Canada
- Mexico
Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Erythropoietin Stimulating Agents Market.

Available Customizations:

Global Erythropoietin Stimulating Agents Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Feed Phytogenic Market

5. Voice of Customer

6. Global Erythropoietin Stimulating Agents Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type (Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, And Other Types)
- 6.2.2. By Application (Cancer, Renal Disorders, Anti-retroviral Treatment, Neural Diseases, and Other Applications)
- 6.2.3. By Region
- 6.2.4. By Company (2024)
6.3. Market Map

7. Asia Pacific Erythropoietin Stimulating Agents Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Application
- 7.2.3. By Country
7.3. Asia Pacific: Country Analysis
- 7.3.1. China Erythropoietin Stimulating Agents Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Application
- 7.3.2. India Erythropoietin Stimulating Agents Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Application
- 7.3.3. Australia Erythropoietin Stimulating Agents Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Application
- 7.3.4. Japan Erythropoietin Stimulating Agents Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Application
- 7.3.5. South Korea Erythropoietin Stimulating Agents Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Application

8. Europe Erythropoietin Stimulating Agents Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Application
- 8.2.3. By Country
8.3. Europe: Country Analysis
- 8.3.1. France Erythropoietin Stimulating Agents Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Application
- 8.3.2. Germany Erythropoietin Stimulating Agents Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Application
- 8.3.3. Spain Erythropoietin Stimulating Agents Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Application
- 8.3.4. Italy Erythropoietin Stimulating Agents Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Application
- 8.3.5. United Kingdom Erythropoietin Stimulating Agents Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Application

9. North America Erythropoietin Stimulating Agents Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Application
- 9.2.3. By Country
9.3. North America: Country Analysis
- 9.3.1. United States Erythropoietin Stimulating Agents Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Application
- 9.3.2. Mexico Erythropoietin Stimulating Agents Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Application
- 9.3.3. Canada Erythropoietin Stimulating Agents Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Application

10. South America Erythropoietin Stimulating Agents Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Application
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Erythropoietin Stimulating Agents Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Application
- 10.3.2. Argentina Erythropoietin Stimulating Agents Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Application
- 10.3.3. Colombia Erythropoietin Stimulating Agents Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Application

11. Middle East and Africa Erythropoietin Stimulating Agents Market Outlook

11.1. Market Size & Forecast
- 11.1.1. By Value
11.2. Market Share & Forecast
- 11.2.1. By Type
- 11.2.2. By Application
- 11.2.3. By Country
11.3. MEA: Country Analysis
- 11.3.1. South Africa Erythropoietin Stimulating Agents Market Outlook
  - 11.3.1.1. Market Size & Forecast
    - 11.3.1.1.1. By Value
  - 11.3.1.2. Market Share & Forecast
    - 11.3.1.2.1. By Type
    - 11.3.1.2.2. By Application
- 11.3.2. Saudi Arabia Erythropoietin Stimulating Agents Market Outlook
  - 11.3.2.1. Market Size & Forecast
    - 11.3.2.1.1. By Value
  - 11.3.2.2. Market Share & Forecast
    - 11.3.2.2.1. By Type
    - 11.3.2.2.2. By Application
- 11.3.3. UAE Erythropoietin Stimulating Agents Market Outlook
  - 11.3.3.1. Market Size & Forecast
    - 11.3.3.1.1. By Value
  - 11.3.3.2. Market Share & Forecast
    - 11.3.3.2.1. By Type
    - 11.3.3.2.2. By Application

12. Market Dynamics

12.1. Drivers
12.2. Challenges

13. Market Trends & Developments

13.1. Recent Developments
13.2. Product Launches
13.3. Mergers & Acquisitions

14. Global Erythropoietin Stimulating Agents Market: SWOT Analysis

15. Porter's Five Forces Analysis

15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Product

16. PESTLE Analysis

17. Competitive Landscape

17.1. Amgen Inc.
- 17.1.1. Business Overview
- 17.1.2. Company Snapshot
- 17.1.3. Products & Services
- 17.1.4. Financials (In case of listed companies)
- 17.1.5. Recent Developments
- 17.1.6. SWOT Analysis
17.2. Biocon Limited
17.3. Celltrion Inc.
17.4. F. Hoffmann-La Roche Ltd
17.5. Intas Pharmaceuticals Ltd
17.6. Johnson and Johnson
17.7. Pfizer Inc.
17.8. Teva Pharmaceutical Industries Ltd
17.9. Thermo Fisher Scientific
17.10. LG Lifesciences, Ltd
17.11. Novartis AG(Sandoz)
17.12. Panacea Biotec Ltd